Measuring the tolerance of the genetic code to altered codon size

  1. Erika Alden DeBenedictis  Is a corresponding author
  2. Dieter Söll
  3. Kevin M Esvelt
  1. Massachusetts Institue of Technology, United States
  2. Yale University, United States
  3. Massachusetts Institute of Technology, United States

Abstract

Translation using four-base codons occurs in both natural and synthetic systems. What constraints contributed to the universal adoption of a triplet-codon, rather than quadruplet-codon, genetic code? Here, we investigate the tolerance of the Escherichia coli genetic code to tRNA mutations that increase codon size. We found that tRNAs from all twenty canonical isoacceptor classes can be converted to functional quadruplet tRNAs (qtRNAs). Many of these selectively incorporate a single amino acid in response to a specified four-base codon, as confirmed with mass spectrometry. However, efficient quadruplet codon translation often requires multiple tRNA mutations. Moreover, while tRNAs were largely amenable to quadruplet conversion, only nine of the twenty aminoacyl tRNA synthetases tolerate quadruplet anticodons. These may constitute a functional and mutually orthogonal set, but one that sharply limits the chemical alphabet available to a nascent all-quadruplet code. Our results suggest that the triplet codon code was selected because it is simpler and sufficient, not because a quadruplet codon code is unachievable. These data provide a blueprint for synthetic biologists to deliberately engineer an all-quadruplet expanded genetic code.

Data availability

All luminescence raw data are compiled in Figure 5A and provided as Source Data 1. Raw spectra have been deposited in the PRIDE database, dataset identifier PXD031925 and 10.6019/PXD031925.

The following data sets were generated

Article and author information

Author details

  1. Erika Alden DeBenedictis

    Department of Biological Engineering, Massachusetts Institue of Technology, Cambridge, United States
    For correspondence
    erika.alden@mit.edu
    Competing interests
    Erika Alden DeBenedictis, filed US Patent 16405380 on tRNA sequences engineered in this work...
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7933-2651
  2. Dieter Söll

    Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3077-8986
  3. Kevin M Esvelt

    Department of Media Arts and Sciences, Massachusetts Institute of Technology, Cambridge, United States
    Competing interests
    Kevin M Esvelt, filed US Patent 16405380 on tRNA sequences engineered in this work...
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8797-3945

Funding

National Institute of General Medical Sciences (R35GM122560)

  • Dieter Söll

National Institute of General Medical Sciences (3R35GM122560-05W1)

  • Dieter Söll

National Institute of Allergy and Infectious Diseases (F31 AI145181-01)

  • Erika Alden DeBenedictis

National Institute of Diabetes and Digestive and Kidney Diseases (R00 DK102669-01)

  • Kevin M Esvelt

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Timothy W Nilsen, Case Western Reserve University, United States

Version history

  1. Preprint posted: April 26, 2021 (view preprint)
  2. Received: January 10, 2022
  3. Accepted: March 15, 2022
  4. Accepted Manuscript published: March 16, 2022 (version 1)
  5. Version of Record published: May 11, 2022 (version 2)

Copyright

© 2022, DeBenedictis et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,438
    views
  • 577
    downloads
  • 13
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Erika Alden DeBenedictis
  2. Dieter Söll
  3. Kevin M Esvelt
(2022)
Measuring the tolerance of the genetic code to altered codon size
eLife 11:e76941.
https://doi.org/10.7554/eLife.76941

Share this article

https://doi.org/10.7554/eLife.76941

Further reading

    1. Biochemistry and Chemical Biology
    Pattama Wiriyasermkul, Satomi Moriyama ... Shushi Nagamori
    Research Article

    Transporter research primarily relies on the canonical substrates of well-established transporters. This approach has limitations when studying transporters for the low-abundant micromolecules, such as micronutrients, and may not reveal physiological functions of the transporters. While d-serine, a trace enantiomer of serine in the circulation, was discovered as an emerging biomarker of kidney function, its transport mechanisms in the periphery remain unknown. Here, using a multi-hierarchical approach from body fluids to molecules, combining multi-omics, cell-free synthetic biochemistry, and ex vivo transport analyses, we have identified two types of renal d-serine transport systems. We revealed that the small amino acid transporter ASCT2 serves as a d-serine transporter previously uncharacterized in the kidney and discovered d-serine as a non-canonical substrate of the sodium-coupled monocarboxylate transporters (SMCTs). These two systems are physiologically complementary, but ASCT2 dominates the role in the pathological condition. Our findings not only shed light on renal d-serine transport, but also clarify the importance of non-canonical substrate transport. This study provides a framework for investigating multiple transport systems of various trace micromolecules under physiological conditions and in multifactorial diseases.

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Natalia Dolgova, Eva-Maria E Uhlemann ... Oleg Y Dmitriev
    Research Article

    Mediator of ERBB2-driven Cell Motility 1 (MEMO1) is an evolutionary conserved protein implicated in many biological processes; however, its primary molecular function remains unknown. Importantly, MEMO1 is overexpressed in many types of cancer and was shown to modulate breast cancer metastasis through altered cell motility. To better understand the function of MEMO1 in cancer cells, we analyzed genetic interactions of MEMO1 using gene essentiality data from 1028 cancer cell lines and found multiple iron-related genes exhibiting genetic relationships with MEMO1. We experimentally confirmed several interactions between MEMO1 and iron-related proteins in living cells, most notably, transferrin receptor 2 (TFR2), mitoferrin-2 (SLC25A28), and the global iron response regulator IRP1 (ACO1). These interactions indicate that cells with high MEMO1 expression levels are hypersensitive to the disruptions in iron distribution. Our data also indicate that MEMO1 is involved in ferroptosis and is linked to iron supply to mitochondria. We have found that purified MEMO1 binds iron with high affinity under redox conditions mimicking intracellular environment and solved MEMO1 structures in complex with iron and copper. Our work reveals that the iron coordination mode in MEMO1 is very similar to that of iron-containing extradiol dioxygenases, which also display a similar structural fold. We conclude that MEMO1 is an iron-binding protein that modulates iron homeostasis in cancer cells.